Wang Pengcheng, Shehu Amina I, Ma Xiaochao
Center for Pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
Curr Pharmacol Rep. 2017 Feb;3(1):10-15. doi: 10.1007/s40495-016-0079-5. Epub 2017 Jan 3.
Although safety of drug candidates is carefully monitored in preclinical and clinical studies using a variety of approaches, drug toxicity may still occur in clinical practice. Therefore, novel approaches are needed to complement the current drug safety evaluation system. Metabolomics comprehensively analyzes the metabolites altered by drug exposure, which can therefore be used to profile drug metabolism, endobiotic metabolism, and drug-microbiota interactions. The information from metabolomic analysis can be used to determine the off-targets of a drug candidate, and thus provide a mechanistic understanding of drug toxicity. We herein discuss the opportunities of metabolomics in drug safety evaluation.
尽管在临床前和临床研究中使用了多种方法对候选药物的安全性进行了仔细监测，但在临床实践中仍可能发生药物毒性。因此，需要新的方法来补充当前的药物安全性评估系统。代谢组学全面分析药物暴露后改变的代谢物，因此可用于描绘药物代谢、内源性代谢和药物-微生物群相互作用。代谢组学分析的信息可用于确定候选药物的脱靶效应，从而提供对药物毒性的机制性理解。我们在此讨论代谢组学在药物安全性评估中的机遇。
